<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We propose that there are two main classes of Epstein-Barr virus (EBV) associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo>: primarily malignant Burkitt's <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), on one hand, and primarily benign lymphoproliferations, e.g., post-transplant <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (PTLD) on the other hand </plain></SENT>
<SENT sid="1" pm="."><plain>PTLD may start as a benign lymphoproliferation which becomes malignant if out of T cell control for too long </plain></SENT>
<SENT sid="2" pm="."><plain>Our discovery of a binding site for the oncoprotein c-Myc at a central position of the EBV genome favours a distinction of pathogenetic pathways or scenarios for the proposed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> classes </plain></SENT>
<SENT sid="3" pm="."><plain>In the first scenario nuclear maintenance of the EBV genome and activation of <z:mp ids='MP_0001799'>viral</z:mp> anti-apoptotic functions with the help of c-Myc are indispensable for the origin of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumours</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) from the germinal centre B-cell </plain></SENT>
<SENT sid="4" pm="."><plain>In the second scenario expression of the main <z:mp ids='MP_0001799'>viral</z:mp> transforming protein EBNA2 is essential for immortalisation and non-malignant morphological transformation of any (germinal centre derived or non-germinal centre) B-cell in the absence of T cell control </plain></SENT>
<SENT sid="5" pm="."><plain>Although EBNA2 expression is permissible, under specific circumstances, in malignant B-cells, it is not required for <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
</text></document>